Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.
Farzana Yasmin ZamanAshwin SubramaniamAfsana AfrozZarka SamoonDaniel J GoughSurein ArulanandaMuhammad AlamgeerPublished in: Cancers (2023)
This large systematic review, despite heterogeneity, found that baseline negative ctDNA levels and early reduction in ctDNA following treatment could be strong prognostic markers for PFS and OS in patients undergoing targeted therapies for advanced NSCLC. Future randomised clinical trials should incorporate serial ctDNA monitoring to further establish the clinical utility in advanced NSCLC management.
Keyphrases
- circulating tumor
- clinical trial
- systematic review
- circulating tumor cells
- cell free
- small cell lung cancer
- patients undergoing
- meta analyses
- advanced non small cell lung cancer
- open label
- randomized controlled trial
- single cell
- phase ii
- double blind
- study protocol
- tyrosine kinase
- replacement therapy
- placebo controlled